Trial Profile

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jun 2025 According to a Cabaletta Bio media release, new clinical and translational data from RESET-Myositis, RESET-SLE and RESET-SSc trials evaluating rese-cel study being presented in three oral presentations at the ongoing European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, in Barcelona, Spain.
11 Jun 2025 Results presented in the Cabaletta Bio Media Release
15 May 2025 According to a Cabaletta Bio media release, systemic sclerosis registrational discussions with FDA anticipated in 4Q 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com